[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

GT201300215A - Inhibidores de glucosilceramida sintasa - Google Patents

Inhibidores de glucosilceramida sintasa

Info

Publication number
GT201300215A
GT201300215A GT201300215A GT201300215A GT201300215A GT 201300215 A GT201300215 A GT 201300215A GT 201300215 A GT201300215 A GT 201300215A GT 201300215 A GT201300215 A GT 201300215A GT 201300215 A GT201300215 A GT 201300215A
Authority
GT
Guatemala
Prior art keywords
glucosilceramide
inhibitors
sintasa
invention refers
metabolic diseases
Prior art date
Application number
GT201300215A
Other languages
English (en)
Inventor
Elyse Bourque
Cassandra Celatka
Bradford Hirth
Markus Metz
Zhong Zhao
Renato Skerlj
Yibin Xiang
Katherine Jancsics
John Marshall
Seng Cheng
Ronald Scheule
Mario Cabrera-Salazar
Andrew Good
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of GT201300215A publication Critical patent/GT201300215A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/02—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing not further condensed quinolizine ring systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01022—Alpha-galactosidase (3.2.1.22)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE EN GENERAL AL CAMPO DE COMPUESTOS TERAPÉUTICOS PARA ENFERMEDADES CANCEROSAS Y METABÓLICAS. MÁS ESPECÍFICAMENTE, LA INVENCIÓN SE REFIERE A INHIBIDORES DE GLUCOSILCERAMIDA SINTASA (GCS) ÚTILES PARA EL TRATAMIENTO DE ENFERMEDADES METABÓLICAS, TALES COMO ENFERMEDADES DE ALMACENAMIENTO LISOSÓMICO, SOLOS O EN COMBINACIÓN CON TERAPIA DE REEMPLAZO ENZIMÁTICO Y/O PARA EL TRATAMIENTO DEL CÁNCER
GT201300215A 2011-03-18 2013-09-18 Inhibidores de glucosilceramida sintasa GT201300215A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161454034P 2011-03-18 2011-03-18
US201261590711P 2012-01-25 2012-01-25

Publications (1)

Publication Number Publication Date
GT201300215A true GT201300215A (es) 2015-02-09

Family

ID=46879977

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201300215A GT201300215A (es) 2011-03-18 2013-09-18 Inhibidores de glucosilceramida sintasa

Country Status (36)

Country Link
US (5) US9139580B2 (es)
EP (2) EP2685986B1 (es)
JP (2) JP6117708B2 (es)
KR (1) KR101987736B1 (es)
CN (2) CN103917094B (es)
AR (1) AR085425A1 (es)
AU (2) AU2012231275A1 (es)
BR (2) BR112013023774B1 (es)
CA (1) CA2830540C (es)
CL (1) CL2013002688A1 (es)
CO (1) CO6801749A2 (es)
CR (1) CR20190034A (es)
DK (1) DK2685986T3 (es)
DO (1) DOP2013000209A (es)
EC (1) ECSP13012978A (es)
ES (1) ES2774293T3 (es)
GT (1) GT201300215A (es)
HR (1) HRP20200226T1 (es)
HU (1) HUE047888T2 (es)
IL (1) IL228514B (es)
LT (1) LT2685986T (es)
MA (1) MA35023B1 (es)
MX (3) MX368340B (es)
MY (1) MY173998A (es)
NI (1) NI201300083A (es)
PE (1) PE20140412A1 (es)
PL (1) PL2685986T3 (es)
PT (1) PT2685986T (es)
RS (1) RS59963B1 (es)
RU (2) RU2018104472A (es)
SI (1) SI2685986T1 (es)
TW (2) TWI546301B (es)
UA (1) UA118248C2 (es)
UY (1) UY33958A (es)
WO (1) WO2012129084A2 (es)
ZA (1) ZA201307016B (es)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2685986T3 (pl) * 2011-03-18 2020-07-27 Genzyme Corporation Inhibitor syntazy glukozyloceramidowej
MA37975B2 (fr) * 2012-09-11 2021-03-31 Genzyme Corp Inhibiteurs de synthase de glucosylcéramide
AU2019222801B2 (en) * 2012-09-11 2021-02-18 Genzyme Corporation Glucosylceramide synthase inhibitors
MX365464B (es) * 2013-03-15 2019-06-04 Genzyme Corp Prodecimiento para preparar inhibidores de la glucosilceramida sintasa.
JO3713B1 (ar) * 2013-03-15 2021-01-31 Genzyme Corp أشكال ملح (s)-كوينوكليدين-3-يل(2-(2-(4-فلوروفينيل)ثيازول-4-يل)بروبان-2-يل)كارباميت
CN104418851A (zh) * 2013-09-02 2015-03-18 上海龙翔生物医药开发有限公司 奎宁环衍生物的制备方法及纯化方法
CN117679415A (zh) * 2013-12-11 2024-03-12 建新公司 葡糖神经酰胺合酶抑制剂
JP6836502B2 (ja) * 2014-05-30 2021-03-03 スプハエラ ファーマ ピーヴィーティー リミテッド 抗結核薬としての新規な化合物
JP6749923B2 (ja) 2015-02-02 2020-09-02 ザ リージェンツ オブ ザ ユニバーシティー オブ ミシガン グルコシルセラミドシンターゼ阻害剤及びそれを使用した治療方法
TW201642855A (zh) * 2015-03-10 2016-12-16 健臻公司 用於治療蛋白質病變之方法
JP2018525345A (ja) 2015-07-01 2018-09-06 ノースウェスタン ユニバーシティ 置換キナゾリン化合物及びグルコセレブロシダーゼ活性の調節のためのその使用
JP2018522872A (ja) * 2015-07-01 2018-08-16 ノースウェスタン ユニバーシティ 置換４−メチルピロロ［１，２−ａ］ピリミジン−８−カルボキサミド化合物及びグルコセレブロシダーゼ活性の調節のためのその使用
AR107483A1 (es) 2016-01-29 2018-05-02 Hanmi Pharm Ind Co Ltd Conjugado de enzimas terapéuticas
KR20180124971A (ko) 2016-03-25 2018-11-21 젠자임 코포레이션 단백질병증의 바이오마커 및 이의 용도
EP3318277A1 (en) 2016-11-04 2018-05-09 Institut du Cerveau et de la Moelle Epiniere-ICM Inhibitors of glucosylceramide synthase for the treatment of motor neuron diseases
CA3043709A1 (en) 2016-11-14 2018-05-17 Berg Llc Methods for treating parkinson's disease
CN110494432B (zh) 2016-12-28 2022-08-12 米尼奥尔克斯治疗有限公司 异喹啉化合物，其制备方法及其在与β-半乳糖苷酶活性改变相关的病症中的治疗用途
BR112019013571A2 (pt) 2016-12-29 2020-01-07 Minoryx Therapeutics S.L. Compostos heteroarila e seu uso
CN108341822B (zh) * 2017-01-23 2021-04-16 广州市恒诺康医药科技有限公司 Fxr受体调节剂及其制备方法和应用
WO2019099294A1 (en) * 2017-11-14 2019-05-23 Merck Sharp & Dohme Corp. Novel substituted biaryl compounds as indoleamine 2,3-dioxygenase (ido) inhibitors
US20200339587A1 (en) 2017-12-21 2020-10-29 Lysosomal Therapeutics Inc. Crystalline substituted cyclohexyl pyrazolo[1,5-a]pyrimidinyl carboxamide compound and therapeutic uses thereof
US11459325B2 (en) 2018-01-31 2022-10-04 Takeda Pharmaceutical Company Limited Heterocyclic compound
US10519157B2 (en) * 2018-02-09 2019-12-31 X-Cutag Therapeutics, Inc. Deuterated compounds for treating Fabry, Gaucher, Parkinson's and related diseases and conditions, and compositions and methods thereof
KR102233530B1 (ko) * 2018-11-22 2021-03-31 (주)프로스테믹스 엑소좀 및 이의 다양한 용도
KR102342901B1 (ko) * 2018-11-22 2021-12-24 (주)프로스테믹스 엑소좀 및 이의 다양한 용도
KR102342902B1 (ko) * 2018-11-22 2021-12-24 (주)프로스테믹스 엑소좀 및 이의 다양한 용도
JP7511567B2 (ja) * 2019-02-04 2024-07-05 ジェンザイム・コーポレーション リソソーム蓄積性疾患と関連する症状および障害を処置するための方法
CN114040762A (zh) 2019-02-04 2022-02-11 建新公司 使用葡糖神经酰胺合酶(gcs)的抑制剂治疗纤毛疾病
WO2020193746A1 (en) 2019-03-28 2020-10-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival of patients suffering from melanoma
JP7539382B2 (ja) 2019-07-29 2024-08-23 武田薬品工業株式会社 複素環化合物
EP4048397B1 (en) 2019-10-23 2023-08-16 The Regents Of The University Of Michigan Glucosylceramide synthase inhibitors for therapeutic applications
PL4041733T3 (pl) * 2019-11-15 2024-09-23 Yuhan Corporation Pochodne mające ugrupowanie 2,3-dihydro-1h-indenu lub 2,3-dihydrobenzofuranu lub ich farmaceutycznie dopuszczalne sole oraz kompozycje farmaceutyczne je zawierające
JP2023503832A (ja) * 2019-11-15 2023-02-01 ユーハン・コーポレイション １，２，３，４－テトラヒドロナフタレン基を有する新規な誘導体またはその薬学的に許容可能な塩及びこれらを含む医薬組成物
KR20220150880A (ko) 2019-11-25 2022-11-11 게인 테라퓨틱스 에스에이 아릴 및 헤테로아릴 화합물, 및 갈락토세레브로시다제의 활성 변경과 관련된 병태에서의 치료 용도
WO2021105908A1 (en) 2019-11-25 2021-06-03 Gain Therapeutics Sa Heteroaryl compounds and therapeutic uses thereof in conditions associated with the alteration of the activity of beta-glucocerebrosidase
TW202142236A (zh) * 2020-02-03 2021-11-16 美商健臻公司 用於治療與溶體儲積症相關的神經症狀之方法
AU2021217816A1 (en) 2020-02-03 2022-08-11 Gt Gain Therapeutics Sa Combination therapy for treating MPS1
WO2021214771A1 (en) 2020-04-23 2021-10-28 The Israel Institute of Biological Research (IIBR) Glucosylceramide synthase inhibitors for prevention and treatment of viral diseases
JP2023523454A (ja) 2020-04-28 2023-06-05 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン グルコシルセラミド合成酵素のピリジン阻害剤及びそれらを使用する治療方法
MX2023001014A (es) 2020-07-24 2023-03-01 Genzyme Corp Composiciones farmaceuticas que comprenden venglustat.
WO2022240116A1 (en) * 2021-05-11 2022-11-17 Yuhan Corporation Novel compounds having inhibitory activity against glucosylceramide synthase or pharmaceutically acceptable salt thereof, processes for preparing the same, and pharmaceutical compositions comprising the same
WO2023042177A1 (en) 2021-09-20 2023-03-23 Gt Gain Therapeutics Sa Enantiomers of 5-((7-chloroisoquinolin-1-yl)amino)-n-(6-methoxy-1,2,3,4-tetrahydronaphthalen-2-yl)picolinamide
WO2023239892A1 (en) * 2022-06-10 2023-12-14 Arkuda Therapeutics Compounds for modulation of cd68 and uses thereof
WO2024090919A1 (en) * 2022-10-24 2024-05-02 Yuhan Corporation Improved processes for preparing dimethyl-2,3-dihydro-1h-indene derivatives
WO2024090917A1 (en) * 2022-10-24 2024-05-02 Yuhan Corporation Novel salt of dimethyl-2,3-dihydro-1h-indene derivative and processes for preparing the same
WO2024116127A1 (en) 2022-12-01 2024-06-06 Genzyme Corporation Venglustat in combination with a strong or moderate inhibitor of cyp3a4
WO2024141998A1 (en) 2022-12-30 2024-07-04 Gt Gain Therapeutics Sa Method of treating tauopathies
CN118496159B (zh) * 2024-07-18 2024-09-24 广州医科大学附属市八医院 一种化合物在制备具有预防和/或治疗肝纤维化作用的药物中的应用

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE640616A (es) 1962-12-19
US3492397A (en) 1967-04-07 1970-01-27 Warner Lambert Pharmaceutical Sustained release dosage in the pellet form and process thereof
US4060598A (en) 1967-06-28 1977-11-29 Boehringer Mannheim G.M.B.H. Tablets coated with aqueous resin dispersions
US3538214A (en) 1969-04-22 1970-11-03 Merck & Co Inc Controlled release medicinal tablets
US4173626A (en) 1978-12-11 1979-11-06 Merck & Co., Inc. Sustained release indomethacin
WO1988002477A1 (en) * 1986-10-03 1988-04-07 Micro Motion, Inc. Density insensitive coriolis mass flow rate meter
IE62231B1 (en) 1987-12-24 1995-01-11 Wyeth John & Brother Ltd Heterocyclic compounds
US5236838A (en) 1988-12-23 1993-08-17 Genzyme Corporation Enzymatically active recombinant glucocerebrosidase
US5549892A (en) 1988-12-23 1996-08-27 Genzyme Corporation Enhanced in vivo uptake of glucocerebrosidase
IT1228293B (it) * 1989-02-06 1991-06-07 Angeli Inst Spa Benzoderivati di composti eterociclici contenenti azoto.
US5272071A (en) 1989-12-22 1993-12-21 Applied Research Systems Ars Holding N.V. Method for the modification of the expression characteristics of an endogenous gene of a given cell line
US5968502A (en) 1991-11-05 1999-10-19 Transkaryotic Therapies, Inc. Protein production and protein delivery
EP0747355A4 (en) 1994-02-10 1997-04-09 Yamanouchi Pharma Co Ltd NEW CARBAMATES AND MEDICINAL PRODUCTS CONTAINING THEM
JPH08198751A (ja) * 1995-01-19 1996-08-06 Yamanouchi Pharmaceut Co Ltd カルバメート誘導体
KR19990067403A (ko) * 1995-11-08 1999-08-16 이곤 이 버그 1-아자바이시클로헵탄 유도체 및 이의 약제학적용도
IL135578A0 (en) 1997-10-29 2001-05-20 Genzyme Corp Compositions and methods for treating lysosomal storage disease
US6953855B2 (en) * 1998-12-11 2005-10-11 Targacept, Inc. 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
FR2791678B1 (fr) 1999-03-30 2001-05-04 Synthelabo Derives de 1,4-diazabicyclo [3.2.2] nonane-4-carboxylates et -carboxamides, leur preparation et leur application en therapeutique
GB0010955D0 (en) * 2000-05-05 2000-06-28 Novartis Ag Organic compounds
JP4445704B2 (ja) * 2000-12-22 2010-04-07 アルミラル・ソシエダッド・アノニマ キヌクリジンカルバメート誘導体およびｍ３アンダゴニストとしてのそれらの使用
ATE348829T1 (de) * 2001-02-06 2007-01-15 Pfizer Prod Inc Pharmazeutische zusammensetzungen zur behandlung von störungen des zns oder anderen erkrankungen
JP2003267977A (ja) * 2002-03-14 2003-09-25 Yamanouchi Pharmaceut Co Ltd キヌクリジン誘導体
ES2203327B1 (es) * 2002-06-21 2005-06-16 Almirall Prodesfarma, S.A. Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen.
US7985760B2 (en) * 2002-07-17 2011-07-26 Actelion Pharmaceuticals Ltd. Piperidinetriol derivatives as inhibitors of glycosyceramid synthase
WO2004011430A1 (ja) 2002-07-25 2004-02-05 Yamanouchi Pharmaceutical Co., Ltd. ナトリウムチャネル阻害剤
SE0202598D0 (sv) * 2002-09-02 2002-09-02 Astrazeneca Ab Alpha-7 Nicotinic receptor agonists and statins in combination
DE60317564T2 (de) * 2002-12-06 2008-10-23 The Feinstein Institute For Medical Research Hemmung von entzündungen unter verwendung von alpha-7-rezeptor verbindenden cholinergen agonisten
GB0400812D0 (en) 2004-01-14 2004-02-18 Celltech R&D Ltd Novel compounds
JP2007186422A (ja) 2004-01-28 2007-07-26 Astellas Pharma Inc アリールスルフィド誘導体
CA2571584A1 (en) * 2004-06-23 2006-01-05 The Feinstein Institute For Medical Research Method of treating ileus by pharmacological activation of cholinergic receptors
EP1811991B1 (en) 2004-11-10 2018-11-07 Genzyme Corporation Treatment of type 2 diabetes using inhibitors of glycosphingolipid synthesis
US20090318491A1 (en) * 2006-01-27 2009-12-24 Yale Univeristy Cytisine and Acetylcholine Analogs and Methods of Treating Mood Disorders
US7840109B2 (en) * 2006-08-14 2010-11-23 Adc Telecommunications, Inc. Factory spliced cable assembly
WO2009073564A1 (en) * 2007-11-29 2009-06-11 The Hospital For Sick Children Compositions and methods for treating lysosomal disorders
JP2011529500A (ja) * 2008-07-28 2011-12-08 ジェンザイム コーポレーション 虚脱性糸球体症および他の糸球体疾患の処置のためのグルコシルセラミドシンターゼ阻害
WO2010015816A2 (en) * 2008-08-06 2010-02-11 Summit Corporation Plc Treatment of lysosomal storage disorders and other proteostatic diseases
EP2154136A1 (en) * 2008-08-08 2010-02-17 CHIESI FARMACEUTICI S.p.A. Quinuclidine carbonate derivatives and medicinal compositions thereof
WO2010091164A1 (en) 2009-02-06 2010-08-12 Exelixis, Inc. Inhibitors of glucosylceramide synthase
WO2010091104A1 (en) * 2009-02-06 2010-08-12 Exelixis, Inc. Glucosylceramide synthase inhibitors
US20100249251A1 (en) * 2009-06-09 2010-09-30 Sundrop Fuels, Inc. Systems and methods for cyclic operations in a fuel synthesis process
HRP20211992T1 (hr) 2009-08-28 2022-04-01 Icahn School Of Medicine At Mount Sinai Zamjenska enzimska terapija povećanjem doze za liječenje nedostatka kiseline sfingomijelinaze
PL2685986T3 (pl) * 2011-03-18 2020-07-27 Genzyme Corporation Inhibitor syntazy glukozyloceramidowej

Also Published As

Publication number Publication date
EP2685986B1 (en) 2019-11-27
RU2018104472A (ru) 2019-02-22
JP2014517808A (ja) 2014-07-24
MX2013010710A (es) 2013-10-17
IL228514B (en) 2019-09-26
KR101987736B1 (ko) 2019-06-11
CN107080747A (zh) 2017-08-22
PE20140412A1 (es) 2014-04-01
WO2012129084A3 (en) 2014-04-24
AU2016244305A1 (en) 2016-11-03
CN103917094B (zh) 2016-11-09
TW201716404A (zh) 2017-05-16
TWI546301B (zh) 2016-08-21
DOP2013000209A (es) 2014-04-15
CL2013002688A1 (es) 2014-03-07
BR122019017719B1 (pt) 2022-08-23
TWI634119B (zh) 2018-09-01
US9126993B2 (en) 2015-09-08
MY173998A (en) 2020-03-03
RU2645675C2 (ru) 2018-02-27
RU2018104472A3 (es) 2021-04-30
RU2013146550A (ru) 2015-04-27
KR20140092239A (ko) 2014-07-23
DK2685986T3 (da) 2020-03-02
RS59963B1 (sr) 2020-03-31
US20140255381A1 (en) 2014-09-11
JP2017141255A (ja) 2017-08-17
JP6420860B2 (ja) 2018-11-07
US20160207933A1 (en) 2016-07-21
UA118248C2 (uk) 2018-12-26
US20210261557A1 (en) 2021-08-26
EP2685986A4 (en) 2015-03-04
HUE047888T2 (hu) 2020-05-28
BR112013023774B1 (pt) 2022-01-11
CN103917094A (zh) 2014-07-09
AU2016244305B2 (en) 2018-05-24
US9139580B2 (en) 2015-09-22
PL2685986T3 (pl) 2020-07-27
ZA201307016B (en) 2014-05-28
WO2012129084A2 (en) 2012-09-27
LT2685986T (lt) 2020-03-10
US20200048266A1 (en) 2020-02-13
SI2685986T1 (sl) 2020-03-31
CR20190034A (es) 2019-05-20
ES2774293T3 (es) 2020-07-20
CN107080747B (zh) 2021-02-26
NI201300083A (es) 2014-02-28
PT2685986T (pt) 2020-03-05
MX365245B (es) 2019-05-28
MA35023B1 (fr) 2014-04-03
BR112013023774A2 (pt) 2016-12-06
NZ615857A (en) 2016-08-26
EP3673906A1 (en) 2020-07-01
JP6117708B2 (ja) 2017-04-19
MX2019008428A (es) 2019-10-30
AR085425A1 (es) 2013-10-02
UY33958A (es) 2012-10-31
CO6801749A2 (es) 2013-11-29
AU2012231275A1 (en) 2013-10-17
IL228514A0 (en) 2013-12-31
TW201300383A (zh) 2013-01-01
CA2830540C (en) 2021-04-27
MX368340B (es) 2019-09-30
ECSP13012978A (es) 2015-04-30
EP2685986A2 (en) 2014-01-22
CA2830540A1 (en) 2012-09-27
HRP20200226T1 (hr) 2020-05-29
US20140371460A1 (en) 2014-12-18

Similar Documents

Publication Publication Date Title
GT201300215A (es) Inhibidores de glucosilceramida sintasa
GT201500051A (es) Inhibidores de glucosilceramida sintasa
CU20150119A7 (es) 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante
CA2900335C (en) Synthetic analogs of epipolythiodioxopiperazines and uses thereof
DOP2012000257A (es) Derivados del acido 1-amino-2-ciclopropiletilboronico
CR20150078A (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
BR112014032990A2 (pt) seringa
PE20150631A1 (es) Formas cristalinas de un modulador del receptor androgenico
AR082340A1 (es) Metodos y composiciones para la terapia del cancer de higado
NI201400073A (es) Compuestos terapéuticamente activos y sus método
DOP2014000062A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
CR20150571A (es) Compuestos y composiciones terapéuticos
ECSP14030779A (es) Inhibidores del nampt
IN2014DN06104A (es)
EA201400165A1 (ru) Частицы на основе полиакрилата, которые содержат активное соединение
UY34615A (es) Nuevos compuestos útiles para el tratamiento de enfermedades degenerativas e inflamatorias.
UY35438A (es) Procedimiento para preparar inhibidores de la glucosilceramida sintasa.
CL2014002978A1 (es) Combinaciones farmacéuticas que contienen un inhibidor de 11-beta-hidroxiesteroide dehidrogenasa para el tratamiento de trastornos metabólicos
UY35439A (es) Formas salinas del (2-(2-(4-fluorofenil)tiazol-4-il)propan-2-il)carbamato de (S)-quinuclidin-3-ilo.
MX2013011124A (es) Compuestos para el tratamiento del sindrome metabolico.
BR112014026326A2 (pt) composição para tratamento de distúrbios metabólicos
CL2014002845A1 (es) Compuestos derivados de pirazol inhibidores de sglt1; metodo para tratar la diabetes; composicion farmaceutica; uso del compuesto para el tratamiento de la diabetes tipo 1 y tipo 2.
AR090085A1 (es) USO DE COMPUESTOS DE 1H-INDAZOL-3-CARBOXAMIDA COMO INHIBIDORES DE GLUCOGENO SINTASA CINASA 3 b
MX356317B (es) Tratamiento de síntomas asociados a gastroparesia femenina.
AR085105A1 (es) Dosificacion para tratamiento con anticuerpos anti-dominio 7 de tipo de factor de crecimiento epidermico (anti-egfl7)